Therefore, we recommend that apart from hormone receptors and HER2/neu, Ki67 should be evaluated in all breast cancers undergoing neoadjuvant chemotherapy to stratify patients who can benefit more from neoadjuvant chemotherapy. The gene discussed is NR4A1; the disease is breast cancer.